PHARMACY

London Drugs announces oral health screenings after successful pilot

BY David Salazar
RICHMOND, British Columbia, Canada — London Drugs announced Friday that it would be holding 15 oral health screening clinics in the Vancouver metro area between April 25 and May 18. The clinic initiative follows a successful pilot in 2015, which featured what the chain said was the first oral cancer screening in a pharmacy. 
 
“What began as a three clinic trial with a dental professional in collaboration with our pharmacists in April 2015, quickly grew to 12 clinics in a matter of weeks, during our first ever attempt at this program,” London Drugs VP pharmacy John Tse said. “There is clearly demand for the oral screening and continued need for awareness of oral cancer and oral cancer prevention.”
 
The screenings for oral cancer — the sixth most-common cancer in the world — are conducted by registered dental hygienist Stacey Rhodes –Nesset and Dr. Ken Neuman, a member of the University of British Columbia’s Faculty of Dentistry. Pharmacists will be able to discuss smoking cessation counseling and HPV vaccination (both risk considerations for oral cancer) at the clinics. 
 
“London Drugs' clinics bring incredible awareness to oral cancer screening and the importance of early detection," Neuman said. "The best way to monitor your oral health is to work with your dental care provider either at the dental office or at a screening clinic such as the one offered at London Drugs. This program is especially popular among individuals who might not regularly visit a dentist."
 
Screenings are done by appointment and cost $25, with $5 being donated to the BC Oral Cancer Prevention Program. Clinics will be held from 3 p.m. to 7 p.m. at the following locations: 
  • April 25: 710 Granville Street, Vancouver, B.C.
  • April 26: Guildford Town Centre, Surrey, B.C.
  • April 27: 2091 West 42nd Avenue, Vancouver, B.C.
  • April 28: 5639 Victoria Drive, Vancouver, B.C.
  • May 2: 5237: 48th Avenue, Delta, B.C.
  • May 3: 15355: 24th Avenue, White Rock, B.C.
  • May 4: 11666 Steveston Highway, Richmond, B.C.
  • May 5: Morgan Crossing, Surrey, B.C.
  • May 9: 555 Sixth Street, New Westminster, B.C.
  • May 10: 20202 66th Avenue, Langley, B.C.
  • May 11: Lougheed Town Centre, Burnaby, B.C.
  • May 12: 22709 Lougheed Highway, Maple Ridge, B.C.
  • May 16: 2032 Lonsdale Avenue, North Vancouver, B.C.
  • May 17: 525 West Broadway, Vancouver, B.C.
  • May 18: 2230 West Broadway, Vancouver, B.C.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Lupin launches generic Femhrt

BY David Salazar
BALTIMORE —  Lupin announced this week that it had launched its Fyavolv tablets, a generic of Femhrt (norethindrone acetate and ethinyl estradiol). The drug is indicated to treat moderate to severe menopause-related vasomotor symptoms and to prevent postmenopausal osteoporosis. 
 
The drug had U.S. sales of about $39 million for the 12 months ended December 2015, according to IMS Health. 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Allergan acquires Topokine Therapeutics

BY David Salazar
DUBLIN and BOSTON — Allergan on Thursday announced that it had acquired topical dermatology company Topokine Therapeutics, which develops medicine for fat reduction.
 
The acquisition saw Allergan pauying $85 million up front alongside success-based development and milestones for Topokine’s XAF5, an under-eye bag treatment. 
 
"The acquisition of Topokine and its XAF5 technology adds an innovative technology to Allergan's industry leading mid-to-late stage pipeline of more than 70 programs and bolsters our leadership in medical aesthetics," said David Nicholson, EVP and president of global brands research and development at Allergan. "XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available for patients. We look forward to continuing the outstanding development work conducted by the Topokine team to bring this innovative medical aesthetic treatment to market."
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?